{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:12:01Z","timestamp":1790305921387,"version":"4.1.0"},"reference-count":117,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:00:00Z","timestamp":1616889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The eradication of infectious diseases has been achieved only once in history, in 1980, with smallpox. Since 1988, significant effort has been made to eliminate poliomyelitis viruses, but eradication is still just out of reach. As the goal of viral disease eradication approaches, the ability to recreate historically eradicated viruses using synthetic biology has the potential to jeopardize the long-term sustainability of eradication. However, the emergence of the severe acute respiratory syndrome-coronavirus (SARS-CoV)-2 pandemic has highlighted our ability to swiftly and resolutely respond to a potential outbreak. This virus has been synthetized faster than any other in the past and is resulting in vaccines before most attenuated candidates reach clinical trials. Here, synthetic biology has the opportunity to demonstrate its truest potential to the public and solidify a footing in the world of vaccines.<\/jats:p>","DOI":"10.3390\/v13040569","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T23:27:25Z","timestamp":1616974045000},"page":"569","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-2421","authenticated-orcid":false,"given":"Jean-Nicolas","family":"Tournier","sequence":"first","affiliation":[{"name":"Microbiology and Infectious Diseases Department, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"},{"name":"CNRS UMR-3569, Innovative Vaccine Laboratory, Virology Department, Institut Pasteur, 75015 Paris, France"},{"name":"Ecole du Val-de-Gr\u00e2ce, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-5213","authenticated-orcid":false,"given":"Joseph","family":"Kononchik","sequence":"additional","affiliation":[{"name":"Microbiology and Infectious Diseases Department, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"},{"name":"US Army Medical Research Institute of Chemical Defense (USAMRICD), 8350 Ricketts Point Rd., Aberdeen Proving Ground, MD 21010, USA"},{"name":"Toxicology and Chemical Risk Department, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,28]]},"reference":[{"key":"ref_1","unstructured":"Fenner, F., Henderson, D.A., Arita, I., JeZek, Z., and Ladnyi, I.D. (1988). Smallpox and Its Eradication, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Najera, J.A., Gonzalez-Silva, M., and Alonso, P.L. (2011). Some lessons for the future from the Global Malaria Eradication Programme (1955\u20131969). PLoS Med., 8.","DOI":"10.1371\/journal.pmed.1000412"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(18)30483-5","article-title":"On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine","volume":"392","author":"Peng","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","article-title":"Current and future influenza vaccines","volume":"25","author":"Yamayoshi","year":"2019","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.1072266","article-title":"Chemical synthesis of poliovirus cDNA: Generation of infectious virus in the absence of natural template","volume":"297","author":"Cello","year":"2002","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Noyce, R.S., Lederman, S., and Evans, D.H. (2018). Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0188453"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Noyce, R.S., and Evans, D.H. (2018). Synthetic horsepox viruses and the continuing debate about dual use research. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007025"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-020-2294-9","article-title":"Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform","volume":"582","author":"Thao","year":"2020","journal-title":"Nature"},{"key":"ref_9","first-page":"47","article-title":"The United States Army and malaria control in World War II","volume":"42","author":"Hays","year":"2000","journal-title":"Parassitologia"},{"key":"ref_10","first-page":"22","article-title":"The principles of disease elimination and eradication","volume":"76","author":"Dowdle","year":"1998","journal-title":"Bull. WHO"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.1119392","article-title":"Characterization of the reconstructed 1918 Spanish influenza pandemic virus","volume":"310","author":"Tumpey","year":"2005","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.109.2822.85","article-title":"Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues","volume":"109","author":"Enders","year":"1949","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zimmermann, M., Hagedorn, B., and Lyons, H. (2019). Projection of costs of polio eradication compared to permanent control. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiz488"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: The epidemiology of poliomyelitis deconstructed","volume":"172","author":"Nathanson","year":"2010","journal-title":"Am. J. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.15585\/mmwr.mm6742a5","article-title":"Update on Vaccine-Derived Polioviruses\u2014Worldwide, January 2017\u2013June 2018","volume":"67","author":"Jorba","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_17","unstructured":"WHO (2020). Global Polio Eradication Intiative, WHO."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1716677","article-title":"Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine","volume":"379","author":"Blake","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.15585\/mmwr.mm6845a5","article-title":"Progress Toward Poliomyelitis Eradication\u2014Pakistan, January 2018-September 2019","volume":"68","author":"Hsu","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.6272391","article-title":"Cloned poliovirus complementary DNA is infectious in mammalian cells","volume":"214","author":"Racaniello","year":"1981","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1073\/pnas.97.10.5516","article-title":"Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome","volume":"97","author":"Almazan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10600","DOI":"10.1128\/JVI.74.22.10600-10611.2000","article-title":"Strategy for systematic assembly of large RNA and DNA genomes: Transmissible gastroenteritis virus model","volume":"74","author":"Yount","year":"2000","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1073\/pnas.97.10.5025","article-title":"The making of infectious viral RNA: No size limit in sight","volume":"97","author":"Lai","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/bit.26890","article-title":"Synthetic biology for bioengineering virus-like particle vaccines","volume":"116","author":"Vidigal","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1473-3099(06)70442-X","article-title":"Deadly \u201cpaleoviruses\u201d: A bioweapon Pandora\u2019s box?","volume":"6","author":"Tournier","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Koblentz, G.D. (2018). A Critical Analysis of the Scientific and Commercial Rationales for the De Novo Synthesis of Horsepox Virus. mSphere, 3.","DOI":"10.1128\/mSphere.00040-18"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Inglesby, T. (2018). Horsepox and the need for a new norm, more transparency, and stronger oversight for experiments that pose pandemic risks. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007129"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/science.359.6374.375","article-title":"Critics see only risks, no benefits in horsepox paper","volume":"359","author":"Kupferschmidt","year":"2018","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3527(00)55001-5","article-title":"DNA vaccines for viral infections: Basic studies and applications","volume":"55","author":"Robinson","year":"2000","journal-title":"Adv. Virus Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-0716-0872-2_2","article-title":"Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination","volume":"2197","author":"Tombacz","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"Rimmelzwaan","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vahedifard, F., and Chakravarthy, K. (2021). Nanomedicine for COVID-19: The role of nanotechnology in the treatment and diagnosis of COVID-19. Emergent Mater., 1\u201325.","DOI":"10.1007\/s42247-021-00168-8"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3389\/fimmu.2019.01250","article-title":"Attenuation of Human Respiratory Viruses by Synonymous Genome Recoding","volume":"10","author":"Collins","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_41","first-page":"E386","article-title":"Genetic stability of genome-scale deoptimized RNA virus vaccine candidates under selective pressure","volume":"114","author":"McCarty","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","unstructured":"Deva Priya, S.A., Kavitha, S., Venugopal, P., Sriram, D.K., and George, M. (2021). Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Clin. Drug Investig., 1\u201311."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bloom, K., van den Berg, F., and Arbuthnot, P. (2020). Self-amplifying RNA vaccines for infectious diseases. Gene Ther.","DOI":"10.1038\/s41434-020-00204-y"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.coviro.2020.08.003","article-title":"A new generation of vaccines based on alphavirus self-amplifying RNA","volume":"44","author":"Vanrell","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7774\/cevr.2021.10.1.6","article-title":"A review on the advancements in the development of vaccines to combat coronavirus disease 2019","volume":"10","author":"Onyeaka","year":"2021","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ymthe.2018.12.013","article-title":"Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice","volume":"27","author":"Samsa","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.vaccine.2016.09.062","article-title":"Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines","volume":"34","author":"Jorritsma","year":"2016","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/1535370216643771","article-title":"Micro- and nanoparticulates for DNA vaccine delivery","volume":"241","author":"Farris","year":"2016","journal-title":"Exp. Biol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1016\/j.vaccine.2011.08.121","article-title":"Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice","volume":"29","author":"Camacho","year":"2011","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.vetpar.2011.05.019","article-title":"Montanide IMS 1313 N VG PR nanoparticle adjuvant enhances antigen-specific immune responses to profilin following mucosal vaccination against Eimeria acervulina","volume":"182","author":"Jang","year":"2011","journal-title":"Vet. Parasitol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.vaccine.2010.12.031","article-title":"An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice","volume":"29","author":"Hu","year":"2011","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Cai, Y., Ye, C., Cheng, B., Nogales, A., Iwasaki, M., Yu, S., Cooper, K., Liu, D.X., Hart, R., and Adams, R. (2020). A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene. mBio, 11.","DOI":"10.1128\/mBio.00039-20"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.virol.2016.11.001","article-title":"Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein","volume":"501","author":"Cheng","year":"2017","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13169","DOI":"10.1073\/pnas.1411290111","article-title":"Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization","volume":"111","author":"Brock","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.virol.2013.12.009","article-title":"Computer-aided codon-pairs deoptimization of the major envelope GP5 gene attenuates porcine reproductive and respiratory syndrome virus","volume":"450\u2013451","author":"Ni","year":"2014","journal-title":"Virology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-020-0176-7","article-title":"Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization","volume":"5","author":"Campagnoli","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sun, J., Zhao, W., Wang, R., Zhang, W., Li, G., Lu, M., Shao, Y., Yang, Y., Wang, N., and Gao, Q. (2020). Analysis of the Codon Usage Pattern of HA and NA Genes of H7N9 Influenza A Virus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197129"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"107586","DOI":"10.1016\/j.celrep.2020.107586","article-title":"Mechanism of Virus Attenuation by Codon Pair Deoptimization","volume":"31","author":"Groenke","year":"2020","journal-title":"Cell Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/JVI.00701-18","article-title":"Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models","volume":"92","author":"Li","year":"2018","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1039\/C4CP05083E","article-title":"Wobble pairs of the HDV ribozyme play specific roles in stabilization of active site dynamics","volume":"17","author":"Sripathi","year":"2015","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1021\/bi970122c","article-title":"Investigation of the structural basis for thermodynamic stabilities of tandem GU wobble pairs: NMR structures of (rGGAGUUCC)2 and (rGGAUGUCC)2","volume":"36","author":"McDowell","year":"1997","journal-title":"Biochemistry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/embo-reports\/kvd001","article-title":"The G x U wobble base pair. A fundamental building block of RNA structure crucial to RNA function in diverse biological systems","volume":"1","author":"Varani","year":"2000","journal-title":"EMBO Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","article-title":"A critical analysis of codon optimization in human therapeutics","volume":"20","author":"Mauro","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_65","first-page":"15643","article-title":"Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design","volume":"10","author":"Kames","year":"2020","journal-title":"bioRxiv"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.celrep.2015.12.011","article-title":"Codon Pair Bias Is a Direct Consequence of Dinucleotide Bias","volume":"14","author":"Kunec","year":"2016","journal-title":"Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/molbev\/msaa188","article-title":"Evidence for Strong Mutation Bias toward, and Selection against, U Content in SARS-CoV-2: Implications for Vaccine Design","volume":"38","author":"Rice","year":"2021","journal-title":"Mol. Biol. Evol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Cheng, S., Wu, H., and Chen, Z. (2020). Evolution of Transmissible Gastroenteritis Virus (TGEV): A Codon Usage Perspective. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217898"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.virol.2019.09.003","article-title":"Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2","volume":"537","author":"Stauft","year":"2019","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s40588-018-0080-3","article-title":"Attenuation of Viruses by Large-Scale Recoding of their Genomes: The Selection Is Always Biased","volume":"5","author":"Osterrieder","year":"2018","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Greenbaum, B.D., Rabadan, R., and Levine, A.J. (2009). Patterns of oligonucleotide sequences in viral and host cell RNA identify mediators of the host innate immune system. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005969"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1093\/nar\/14.13.5125","article-title":"Codon usage in yeast: Cluster analysis clearly differentiates highly and lowly expressed genes","volume":"14","author":"Sharp","year":"1986","journal-title":"Nucleic Acids Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1101\/gr.2896904","article-title":"Codon usage bias from tRNA\u2019s point of view: Redundancy, specialization, and efficient decoding for translation optimization","volume":"14","author":"Rocha","year":"2004","journal-title":"Genome Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Kmiec, D., Nchioua, R., Sherrill-Mix, S., Sturzel, C.M., Heusinger, E., Braun, E., Gondim, M.V.P., Hotter, D., Sparrer, K.M.J., and Hahn, B.H. (2020). CpG Frequency in the 5\u2019 Third of the env Gene Determines Sensitivity of Primary HIV-1 Strains to the Zinc-Finger Antiviral Protein. mBio, 11.","DOI":"10.1128\/mBio.02903-19"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Han, Y., Wang, X., Dang, Y., and Zheng, Y.H. (2008). Demonstration of a novel HIV-1 restriction phenotype from a human T cell line. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002796"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"13509","DOI":"10.1128\/JVI.00402-07","article-title":"The zinc finger antiviral protein acts synergistically with an interferon-induced factor for maximal activity against alphaviruses","volume":"81","author":"MacDonald","year":"2007","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1074276","article-title":"Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein","volume":"297","author":"Gao","year":"2002","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Mao, R., Nie, H., Cai, D., Zhang, J., Liu, H., Yan, R., Cuconati, A., Block, T.M., Guo, J.T., and Guo, H. (2013). Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003494"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Wang, X., Tu, F., Zhu, Y., and Gao, G. (2012). Zinc-finger antiviral protein inhibits XMRV infection. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039159"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/JVI.01601-06","article-title":"Inhibition of filovirus replication by the zinc finger antiviral protein","volume":"81","author":"Muller","year":"2007","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3389\/fmicb.2020.01912","article-title":"Zinc Finger CCCH-Type Antiviral Protein 1 Restricts the Viral Replication by Positively Regulating Type I Interferon Response","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"24303","DOI":"10.1073\/pnas.1913232116","article-title":"Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences","volume":"116","author":"Meagher","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature24039","article-title":"CG dinucleotide suppression enables antiviral defence targeting non-self RNA","volume":"550","author":"Takata","year":"2017","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1093\/nar\/gkz581","article-title":"The role of ZAP and OAS3\/RNAseL pathways in the attenuation of an RNA virus with elevated frequencies of CpG and UpA dinucleotides","volume":"47","author":"Odon","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1089\/jir.2004.24.664","article-title":"Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites","volume":"24","author":"Han","year":"2004","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chom.2012.10.008","article-title":"Codon usage determines the mutational robustness, evolutionary capacity, and virulence of an RNA virus","volume":"12","author":"Lauring","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"17088","DOI":"10.1038\/nmicrobiol.2017.88","article-title":"Attenuation of RNA viruses by redirecting their evolution in sequence space","volume":"2","author":"Moratorio","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Nevot, M., Jordan-Paiz, A., Martrus, G., Andres, C., Garcia-Cehic, D., Gregori, J., Franco, S., Quer, J., and Martinez, M.A. (2018). HIV-1 Protease Evolvability Is Affected by Synonymous Nucleotide Recoding. J. Virol., 92.","DOI":"10.1128\/JVI.00777-18"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Luo, J., Zhang, Y., Zhang, Q., Wu, Y., Zhang, B., Mo, M., Tian, Q., Zhao, J., Mei, M., and Guo, X. (2019). The Deoptimization of Rabies Virus Matrix Protein Impacts Viral Transcription and Replication. Viruses, 12.","DOI":"10.3390\/v12010004"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Mu, Z., Haynes, B.F., and Cain, D.W. (2021). HIV mRNA Vaccines-Progress and Future Paths. Vaccines, 9.","DOI":"10.3390\/vaccines9020134"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/oli.1.1998.8.401","article-title":"Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA","volume":"8","author":"McCluskie","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.20052191","article-title":"All is not Toll: New pathways in DNA recognition","volume":"203","author":"Wagner","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1128\/JVI.01000-07","article-title":"Effects of type I interferons on the adjuvant properties of plasmid granulocyte-macrophage colony-stimulating factor in vivo","volume":"81","author":"Qin","year":"2007","journal-title":"J. Virol."},{"key":"ref_95","first-page":"L796","article-title":"Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors","volume":"276","author":"Li","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/viro.1995.1398","article-title":"Interferon-alpha inhibits the murine cytomegalovirus immediate-early gene expression by down-regulating NF-kappa B activity","volume":"211","author":"Gribaudo","year":"1995","journal-title":"Virology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2\u2032-5\u2032-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acs.bioconjchem.6b00090","article-title":"Effects of Chemically Modified Messenger RNA on Protein Expression","volume":"27","author":"Li","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Pandey, A., Singh, N., Vemula, S.V., Couetil, L., Katz, J.M., Donis, R., Sambhara, S., and Mittal, S.K. (2012). Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033428"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2008.12","article-title":"Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus","volume":"16","author":"Singh","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Garber, D.A., O\u2019Mara, L.A., Zhao, J., Gangadhara, S., An, I., and Feinberg, M.B. (2009). Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005445"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Rghei, A.D., van Lieshout, L.P., Santry, L.A., Guilleman, M.M., Thomas, S.P., Susta, L., Karimi, K., Bridle, B.W., and Wootton, S.K. (2020). AAV Vectored Immunoprophylaxis for Filovirus Infections. Trop. Med. Infect. Dis., 5.","DOI":"10.3390\/tropicalmed5040169"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-0716-0795-4_6","article-title":"Alphavirus-Based Antigen Preparation","volume":"2183","author":"Lundstrom","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Sandbrink, J.B., and Koblentz, G.D. (2021). Biosecurity risks associated with vaccine platform technologies. Vaccine.","DOI":"10.1016\/j.vaccine.2021.02.023"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"185ra68","DOI":"10.1126\/scitranslmed.3006368","article-title":"Synthetic generation of influenza vaccine viruses for rapid response to pandemics","volume":"5","author":"Dormitzer","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2020.02.056","article-title":"A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates","volume":"38","author":"Mueller","year":"2020","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.nanolett.8b00432","article-title":"A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation","volume":"18","author":"Paunovska","year":"2018","journal-title":"Nano Lett."},{"key":"ref_111","unstructured":"U.S. Food & Drug Administration (2021, March 24). Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"(2020). A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect. Dis., 20, 769\u2013770.","DOI":"10.1016\/S1473-3099(20)30426-6"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10654-020-00671-y","article-title":"Vaccine hesitancy: The next challenge in the fight against COVID-19","volume":"35","author":"Dror","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Kremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J.J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., and Schindler, C. (2020). Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers. medRxiv.","DOI":"10.1101\/2020.11.09.20228551"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e00319-17","DOI":"10.1128\/mSphere.00319-17","article-title":"Options for Synthetic DNA Order Screening, Revisited","volume":"2","author":"DiEuliis","year":"2017","journal-title":"mSphere"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/4\/569\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:10:15Z","timestamp":1760364615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/4\/569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,28]]},"references-count":117,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["v13040569"],"URL":"https:\/\/doi.org\/10.3390\/v13040569","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,28]]}}}